Work

Abstract CT212: Elraglusib, a glycogen synthase kinase 3 beta (GSK 3β) inhibitor, plus chemotherapy with or without immunotherapy for advanced salivary gland cancer

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct212

Authors: Glenn J. Hanna, Nicole Scarfo, Kee-Young Shin, Anne ONeill, Michael J. Dennis, Kartik Sehgal, Veronica Bedard, Andrew Mazar, Andrey Ugolkov, Robert I. Haddad

Institutions: Dana-Farber Cancer Institute, Actuate Therapeutics, Inc. (United States)

Language: English

Topic: Salivary Gland Tumors Diagnosis and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409821822

Cites:

Cited by:

Related to: 10